Advanced Enzymes Q2 margin rises to 34% as revenue grows 16%
Key highlights
- Advanced Enzymes' Q2 FY27 revenue rose 16% year on year to Rs 214.5 crore and 12% sequentially.
- Q2 FY27 EBITDA increased 36% sequentially to Rs 72.1 crore, lifting the EBITDA margin to 34% from 28% in Q1 FY27.
- Domestic sales grew 25% year on year to Rs 111 crore and accounted for 52% of Q2 FY27 revenue.
- Bio-Processing was the fastest-growing segment, with revenue up 43% year on year to Rs 36.5 crore.
powered by IRIS

Advanced Enzyme Technologies Limited reported consolidated revenue of Rs 214.5 crore in the second quarter of fiscal year 2027 (Q2 FY27), up 16% year on year and 12% sequentially. Earnings before interest, tax, depreciation and amortisation (EBITDA) margin rose to 34% from 28% in Q1 FY27, while EBITDA increased 36% quarter on quarter to Rs 72.1 crore.
Know Advanced Enzyme Technologies inside out
Results, valuation, peers and who's buying, in one view.
How did Advanced Enzymes perform in Q2 FY27?
Advanced Enzymes increased consolidated revenue to Rs 214.5 crore in Q2 FY27 from Rs 184.5 crore in Q2 FY26, a 16% year-on-year rise, and from Rs 191.7 crore in Q1 FY27, a 12% sequential increase. The quarter ended September 2026, and revenue growth was recorded across Human Nutrition, Animal Nutrition, Bio-Processing and Specialized Manufacturing, with Human Nutrition contributing 60% of quarterly revenue.
Profit after tax (PAT) was Rs 51.2 crore in Q2 FY27, compared with Rs 44.7 crore a year earlier and Rs 38.6 crore in the preceding quarter. Profit before tax (PBT) reached Rs 68.8 crore, rising 15% year on year from Rs 59.5 crore and 28% quarter on quarter from Rs 53.5 crore. Earnings per share increased to Rs 4.33 from Rs 3.87 in Q2 FY26 and Rs 3.31 in Q1 FY27.
Why did Advanced Enzymes' EBITDA margin increase to 34%?
Advanced Enzymes' EBITDA margin increased by six percentage points from 28% in Q1 FY27 to 34% in Q2 FY27, as EBITDA grew 36% to Rs 72.1 crore against revenue growth of 12% to Rs 214.5 crore. The Q2 margin was also one percentage point above the 33% recorded in Q2 FY26, when EBITDA was Rs 60.1 crore on revenue of Rs 184.5 crore.
The reported figures show EBITDA grew faster than revenue in the quarter, but the release does not assign the margin movement to a specific cost item or segment. Financial costs rose to Rs 1.2 crore in Q2 FY27 from Rs 0.6 crore in Q1 FY27 and Rs 0.7 crore in Q2 FY26. Depreciation and amortisation increased to Rs 10.9 crore from Rs 9.9 crore sequentially and Rs 10.1 crore year on year.
PAT margin returned to 24% in Q2 FY27 from 20% in Q1 FY27, matching the margin reported in Q2 FY26. PBT margin was 32% during Q2 FY27, while Advanced Enzymes reported EBITDA margin of 31%, PBT margin of 30% and PAT margin of 22% for H1 FY27. The quarterly EBITDA margin was therefore above the first-half level.
Got a follow-up? Ask IRIS
Which Advanced Enzymes segments drove Q2 revenue growth?
Advanced Enzymes' Bio-Processing segment recorded the fastest Q2 FY27 year-on-year growth at 43%, reaching Rs 36.5 crore, while Animal Nutrition grew 37% to Rs 26.5 crore. Specialized Manufacturing increased 25% to Rs 23.1 crore. Human Nutrition grew 6% to Rs 128.5 crore and remained the largest business by revenue.
Within Bio-Processing, Food revenue rose 48% year on year to Rs 30.5 crore, while Non-Food revenue increased 21% to Rs 6 crore. Advanced Enzymes attributed Human Nutrition growth to improved sales in its Pharma, active pharmaceutical ingredient (API), Biocatalysis and Nutrition businesses. The release does not disclose segment-level profitability, so it does not establish how individual segments affected consolidated EBITDA margin.
On a sequential basis, Bio-Processing also led growth, rising 19% from Rs 30.6 crore in Q1 FY27. Specialized Manufacturing grew 15%, Human Nutrition rose 11%, and Animal Nutrition increased 5%. In Bio-Processing, Food sales rose 16% sequentially to Rs 30.5 crore, while Non-Food sales increased 37% to Rs 6 crore.
How did Advanced Enzymes' domestic and international sales change?
Advanced Enzymes' domestic sales rose 25% year on year to Rs 111 crore in Q2 FY27, while international sales increased 8% to Rs 103.5 crore. Domestic sales represented about 52% of revenue, compared with 48% in Q2 FY26. International sales accounted for 48%, down from 52% a year earlier.
The domestic business also expanded faster sequentially, rising 18% from Rs 93.7 crore in Q1 FY27. International sales increased 6% from Rs 98 crore. India added Rs 17.3 crore of sequential revenue, compared with a Rs 5.5 crore increase in international sales, alongside total consolidated revenue growth of Rs 22.8 crore.
International performance was mixed by region in Q2 FY27. Revenue grew 4% year on year in the Americas, 6% in Asia excluding India, and 15% in the rest of the world, while Europe declined 10%. Compared with Q1 FY27, Europe declined 21%, while the Americas grew 2%, Asia excluding India grew 12%, and the rest of the world rose 103%.
Conclusion
Advanced Enzymes combined a 16% year-on-year revenue increase with EBITDA margin of 34% in Q2 FY27. Bio-Processing, Animal Nutrition and Specialized Manufacturing grew faster than the 6% increase in Human Nutrition, while domestic revenue rose 25% and increased its share of quarterly sales to 52%. PAT increased 14% year on year to Rs 51.2 crore and 33% sequentially.
What to watch next is management's plan to expand probiotic offerings, develop the India business-to-consumer model under the Wellfa nutraceutical brand, and register and launch Animal Nutrition products in domestic and international markets. Advanced Enzymes also said some biocatalysis products for API manufacturers are in advanced plant-level trials, while it has submitted 15 dossiers to the European Food Safety Authority and received positive opinions for nine.


